4,4'-Sulfonyldiphenol - CAS:80-09-1

您当前的位置：

4,4'-Sulfonyldiphenol (Synonyms:4,4-二羟基二苯砜;双酚 S; Bisphenol S; Bis(4-hydroxyphenyl) sulfone)

目录号 : KM32848 CAS No. : 80-09-1 纯度 : 99%

Data Sheet 产品使用指南

4,4'-Sulfonyldiphenol 是一种 Bisphenol A 的替代品，常被广泛应用于工业和消费品中。4,4'-Sulfonyldiphenol 是一种口服有效的雌激素受体 (ER) 激动剂，且能够竞争性结合甲状腺激素受体 (TR)，其对于 TRα 和 TRβ 的 IC50 值分别为 2650 μM 和 2294 μM，从而影响乳腺发育，降低小鼠胎儿睾丸中雄激素受体 (AR) 的表达。4,4'-Sulfonyldiphenol 通过上调 EZH2 介导的 PI3K/AKT/mTOR 通路促进胶质母细胞瘤的进展。4,4'-Sulfonyldiphenol 在慢性暴露下可通过上调 JunB 和 Atf3 导致小鼠肝脏显著脂质沉积和血脂异常，低剂量时具有致肥胖作用。4,4'-Sulfonyldiphenol 通过改变肠道微生物组诱发肠道炎症。4,4'-Sulfonyldiphenol 加速斑马鱼胚胎幼虫动脉粥样硬化的进展。

规格	价格	是否有货	数量
10 mM * 1 mL in DMSO		In-stock
25g		In-stock
50g		In-stock
100g		In-stock
500g		In-stock
1kg		In-stock

查看所有商品（1）

加入购物车大包装询价

Other Forms of Rapamycin:

4,4'-Sulfonyldiphenol In-stock
D-GsMTx4 TFA In-stock
Gambogic amide In-stock
BI-69A11 In-stock
Bakkenolide IIIa In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

4,4'-Sulfonyldiphenol, a substitute for Bisphenol A , is widely used in industrial and consumer products. 4,4'-Sulfonyldiphenol is an oally ative estrogen receptor (ER) agonist and can competitively bind to thyroid hormone receptors (TR) with IC50 values for TRα and TRβ are 2650 μM and 2294 μM respectively, thereby affecting breast development and reducing the expression of androgen receptor (AR) in fetal testes. 4,4'-Sulfonyldiphenol promotes the progression of glioblastoma by upregulating the EZH2 mediated PI3K/AKT/mTOR pathway. Under chronic exposure, 4,4'-Sulfonyldiphenol can cause significant lipid deposition and dyslipidemia in the mouse liver by upregulating JunB and Atf3, and has a role in causing obesity at low doses. 4,4'-Sulfonyldiphenol induces intestinal inflammation by altering the intestinal microbiome. 4,4'-Sulfonyldiphenol accelerates the progression of atherosclerosis in zebrafish embryo larvae。

体外研究

4,4 '- Sulfonyldiphenyl (0-50 μM) can induce thyroid hormone (TH) - dependent proliferation of GH3 cells and inhibit T3 induction in the presence of T3 .
4,4 '- Sulfonyldiphenyl (100 μM, 24 hours) significantly increased lipid deposition in AML12 and primary liver cells via the JunB/ATF3 axis.
4,4 '- Sulfonyldiphenyl (0.001-100 μM, 4-24 hours) promotes proliferation and migration of U-87 MG cells at a concentration of 0.1 µM, and appears to be involved in the EZH2 mediated activation of PI3K/AKT/mTOR pathway .
4,4 '- Sulfonyldiphenol (0.01-1 μM, 0-24 hours) can enhance the formation of oxidized low-density lipoprotein (oxLDL) foam cells in macrophages.

Cell Proliferation Assay

Cell Line:	U-87 MG cells
Concentration:	0, 0.001, 0.01, 0.1, 1, 10 and 100 μM
Incubation Time:	4 and 8 hours
Result:	Significantly increased the proliferation rate at 0.1 μM, and the effect was more significant after 8 hours of treatment than after 4 hours.

Cell Migration Assay

Cell Line:	U-87 MG cells
Concentration:	0.1 μM
Incubation Time:	0, 2, 4, 6, 8, 10 and 12 hours
Result:	Significantly increased the mobility within 12 hours.

Cell Invasion Assay

Cell Line:	U-87 MG cells
Concentration:	0.1, 1 and 10 μM
Incubation Time:	24 hours
Result:	Induced glioblastoma invasion in U-87 MG cells.

CRT-PCR

Cell Line:	U-87 MG cells
Concentration:	0.1 μM
Incubation Time:	4 and 8 hours
Result:	Increased the mRNA level of EZH2.

Western Blot Analysis

Cell Line:	U-87 MG cells
Concentration:	0.1 μM
Incubation Time:	4 and 8 hours
Result:	Increased the expression of EZH2, p-PI3K, p-AKT, p-mTOR and p-4E-BP1. Decreased the expression of PIK3IP1.

体内研究

4,4 '- Sulfonyldiphenyl (2-2000 μg/kg, orally, from day 9 of pregnancy until day 2 or 20 of lactation) alters the growth of breast epithelium and makes male mice more sensitive to additional estrogen exposure during puberty.
4,4 '- Sulfonyldiphenyl (0.2-50 μg/kg, orally, once daily from day 0 of pregnancy until offspring reach 23 weeks of age) can lead to obesity in male mice at low doses, as well as after perinatal and chronic exposure.
4,4 '- Sulfonyldiphenyl (0-10 μM, single dose) can induce TH responsive gene transcription in black spotted lateral fold tadpoles, but changes T3 induced gene transcription in a biphasic concentration response at T3.
4,4 '- Sulfonyldiphenol (0.1-1 mg/kg, gavage, once daily, for 3 months) induced significant lipid deposition and dyslipidemia in the liver of mice, and increased susceptibility to metabolic dysfunction associated fatty liver disease (MASLD).
4,4 '- Sulfonyldiphenol (0.1-1 mg/kg, gavage, once daily, for 3 months) induces intestinal inflammation by altering the gut microbiota of mice.
4,4 '- Sulfonyldiphenol (0-100 μg/L, lasting for 15-45 days) accelerated the progression of atherosclerotic cardiovascular disease (ASCVD) in zebrafish embryonic larva model.

Animal Model:	Long-term and short-term exposure effect assessment established in female CD-1 mice
Dosage:	2 and 200 μg/kg (long-term); 2, 200, and 2000 μg/kg (short-term)
Administration:	Oral administration (p.o.), once daily starting on pregnancy day 9 through lactation day 20 (long-term) and starting on pregnancy day 9 through lactation day 2 (short-term)
Result:	Showed signs of ductal formation in the mammary gland and significantly enlarged the intercellular spaces between the tissues. Increased ERα expression in epithelial cells and dose-dependently decreased AR expression in the stroma. Increased the right duct area in all groups, and the left duct area also increased significantly in the high-dose group. Altered the response of male mice to a pre-pubertal estrogen challenge.

Animal Model:	High fat diet model established in pregnant C57Bl/6J mice
Dosage:	0.2, 1.5, 50 µg/kg
Administration:	Oral administration (p.o.) with water, once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old
Result:	Significantly increased in body weight and fat mass on a high-fat diet. Had no effect on the food intake and energy expenditure. Exhibited a weak but significant hypercholesterolemia with a fold increase of 1.21 and 1.29 at 1.5 and 50 µg/kg, respectively. Showed a significant decrease of the AUC (increase of blood TG clearance). Significantly increased the calculated HOMA-IR index in mice exposed to 1.5 and 50 µg/kg. Induced a significant overexpression of SOCS3 mRNA and a significant mRNA down-regulation of INSR and adiponectin. Induced a weak but significant decrease in mRNA expression of HSL and PPARγ genes in adipose tissue of male mice fed with a HFD.

Animal Model:	MASLD model established in 7-week-old C57BL/6 male mice
Dosage:	0.1 and 1 mg/kg
Administration:	Oral gavage (i.g.), once daily for 3 months
Result:	Induced MASLD phenotype: elevated LDL, increased NEFA, and elevated ALT. Showed obvious lipid droplet accumulation.

分子式

C₁₂H₁₀O₄S

分子量

250.28

CAS号

80-09-1

中文名称

4,4-二羟基二苯砜

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

2-8°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (399.55 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.9955 mL	19.9776 mL	39.9552 mL
5 mM	0.7991 mL	3.9955 mL	7.9911 mL
10 mM	0.3996 mL	1.9978 mL	3.9955 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80 → 45% saline

Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.99 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.99 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。

纯度： 99%

Data Sheet

产品使用指南

Zhang YF, et al. Bisphenol A alternatives bisphenol S and bisphenol F interfere with thyroid hormone signaling pathway in vitro and in vivo. Environ Pollut. 2018 Jun;237:1072-1079.

Li S, et al. Bisphenol S Exposure and MASLD: A Mechanistic Study in Mice. Environ Health Perspect. 2025 May;133(5):57009.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器